Background--Elevated levels of an endogenous Na/K-ATPase inhibitor marinobufagenin accompany salt-sensitive hypertension and are implicated in cardiac fibrosis. Immunoneutralization of marinobufagenin reduces blood pressure in Dahl salt-sensitive (Dahl-S) rats. The effect of the anti-marinobufagenin monoclonal antibody on blood pressure, left ventricular (LV) and renal remodeling, and gene expression were investigated in hypertensive Dahl-S rats.
HS intake in Dahl salt-sensitive (Dahl-S) rats is associated with a hypertensive response accompanied by the development of compensatory left ventricular (LV) hypertrophy, followed by the development of decompensated congestive heart failure (HF). 20, 21 Salt-sensitive hypertension in Dahl-S rats develops as a result of renal Na + retention, which stimulates marinobufagenin increase in parallel with BP elevation. 5, 19, 22 Marinobufagenin induces cardiovascular and renal tissue fibrosis via signaling pathway, [13] [14] [15] which is markedly reduced by administration of anti-marinobufagenin monoclonal antibody (mAb) in the rat model of chronic kidney disease. 11, 15 Fibrotic changes in myocardial and renal tissue in hypertensive Dahl-S rats are accompanied by an activation of transforming growth factor-b (TGFb) signaling. 20, [23] [24] [25] The association of marinobufagenin and TGFb was described in normotensive rats 26 ; however, the studies exploring the causative relationship between marinobufagenin and TGFb in salt-sensitivity are scant.
Dahl-S rat strain was bred for a trait of salt sensitivity. 27 Although it is known what genes participate in the development of hypertension and cardiovascular remodeling, 25, [28] [29] [30] [31] it is not fully understood what signaling mechanism is activated by marinobufagenin via Na/K-ATPase signal transduction in salt sensitivity. The aim of the present study was to investigate genes involved in marinobufagenin-induced cardiovascular and renal remodeling in the Dahl-S rat model of hypertension. We compared the expression of genes in the left ventricle and kidneys in hypertensive Dahl-S rats given an HS intake with and without anti-marinobufagenin mAb administration, which provides a tool in the investigation of the effects of marinobufagenin. We hypothesized that: (1) an elevated marinobufagenin level in hypertensive Dahl-S rats activates cardiovascular and renal TGFb-dependent profibrotic signaling, and (2) immunoneutralization of marinobufagenin by an anti-marinobufagenin mAb will decrease the expression of profibrotic genes, and, thus, diminish tissue fibrosis and improve function of the renal and cardiovascular systems.
Methods
The microarray GEO accession numbers for the data reported in this article are given in the Microarray Data Analysis section. The other data that support the findings of this study are available from the corresponding author upon reasonable request.
Experimental Model
The experimental design of the study was approved by the Animal Care and Use Committee of the Intramural Research Program, National Institute on Aging, National Institutes of Health, and all procedures were performed in accordance with institutional guidelines. Six-week-old, male, Dahl-S rats (SS/ JrHsd; Charles River Laboratories), body weight (BW) 218AE6 g, were placed on a low salt (LS) diet (n=14; 0.1% NaCl; CAT#TD94268; Harlan Laboratories, Inc) or an HS diet (n=14; 8% NaCl; CAT#TD92012; Harlan Laboratories, Inc) and water ad libitum for 8 weeks.
Seven animals from each dietary salt group were treated once with mouse isotype IgG1 (50 lg IgG/kg BW; CAT#-MAB002, clone 11711, R&D Systems, Inc) used as control (LS control [LSC] and HS control [HSC]), or with an antimarinobufagenin mAb (clone 3E9) intraperitoneally (50 lg IgG/kg BW) (groups LSAB and HSAB) at week 7 on HS or LS diets. 32 Antibody was diluted in sterile 0.9% NaCl to the final concentration 50 lg IgG/mL. In our previous publications, 1 week of the marinobufagenin immunoneutralization exhibited antifibrotic effects in a chronic kidney disease model 11 and reduced BP in Dahl-S rats 26 without the adverse effect. Echocardiographic measurements were assessed before and after the antibody treatment (below). Systolic BP was recorded by tail-cuff plethysmography (IITC Life Science Inc) in conscious animals at baseline and before and after the anti-marinobufagenin mAb administration. For each time point, 10 to 15 measurements of BP were performed for each rat; the average of at least 5 stable readings was used.
At the end of week 8, rats were placed in metabolic cages for 24 hours for measurement of water consumption and urine
Clinical Perspective
What Is New?
• The endogenous steroidal Na/K-ATPase inhibitor marinobufagenin is a marker of salt-sensitivity. • In salt-sensitive hypertension, heightened marinobufagenin levels activate cardiac and renal genes and proteins, implicated in profibrotic transforming growth factor-bdependent signaling. • Immunoneutralization of marinobufagenin downregulates genes associated with transforming growth factor-bdependent signaling and heart failure, reverses tissue remodeling, and improves function of the heart and kidneys in hypertensive Dahl salt-sensitive rats.
What Are the Clinical Implications?
• The novel finding that marinobufagenin is an upstream activator in profibrotic transforming growth factor-b signaling implicated in salt-sensitivity phenomena indicates the significance of further studies of the endogenous inhibitors and regulators of Na/K-ATPase in salt-sensitive hypertension in humans. • Immunoneutralization of marinobufagenin can control the exaggerated production of endogenous marinobufagenin, which may be applicable to kidney disease and salt-sensitive hypertension.
output. Animals were deeply anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and euthanized by exsanguination. Blood samples were collected for measurements of plasma marinobufagenin, serum titer of anti-marinobufagenin mAb (below), and erythrocyte Na/K-ATPase activity measurement (below). Wet weight of thoracic aortae, hearts, left ventricles, and kidneys were measured and expressed per BW. Tissues were collected for Western blotting analysis and for the estimation of gene expression by real-time quantitative polymerase chain reaction (qPCR) and microarray analyses (below). The protein and mRNA profiles were assessed in renal medulla because renal tubular cells in the proximal straight tubule and thick ascending limb of Henle's loop are highly responsible for maintaining the salt and water balance of the blood via Na/K-ATPase, which is a target for marinobufagenin. [32] [33] [34] Concentration of urinary Na + was measured with a Roche-Hitachi 917 flame photometry (Roche). Urinary creatinine was estimated with a creatinine assay kit (Cayman Chemical). Plasma electrolytes and creatinine were measured by an i-STAT analyzer (Abbott Laboratories). Fractional excretion of Na + (FENa) was calculated as FENa=(uNa9pCr9100)/ (pNa9uCr), where uNa and pNa are urine Na + and plasma Na + concentrations (mmol/L), respectively, uCr and pCr are urine creatinine and plasma creatinine concentrations (mmol/ L), respectively, and expressed as percent. Creatinine clearance was calculated as (uCr9uVol)/(pCr91440), where uCr and pCr are urine creatinine and plasma creatinine concentrations (mmol/L), respectively; uVol is volume of urine in mL produced during 24 hours, or 1440 minutes, and expressed as mL/min.
Isolated Cardiac Myocytes Studies
Ventricular myocytes were isolated from the hearts of 4-to 5month-old male Dahl-S rats (n=6) kept on an LS diet. 35 Freshly prepared ventricular myocytes were cultured for 2 to 3 hours on the plates coated with 10 to 20 lg/mL Laminin (Sigma-Aldrich Inc) in the culture medium M199 (Sigma-Aldrich Inc). 35 After the cells were attached they were washed 2 or 3 times with the culture medium and were treated for 24 hours with vehicle or with physiological doses of marinobufagenin (1 and 10 nmol/L) as described. 15, 16 Cells were collected and used for Western blotting analysis (below).
Echocardiography
Evaluation of cardiac function and morphology was performed by transthoracic echocardiography (Sonos 5500, Hewlett-Packard) before and after control or anti-marinobufagenin mAb treatment of rats anesthetized by isoflurane (2% in oxygen) 36 in a subcohort of Dahl-S rats (n=5-7 per group). Heart images were obtained in 2-dimensional mode in the parasternal long axis views. The measurements of LV posterior wall thickness and LV internal diameters were made in systole and diastole (LVIDs and LVIDd). LV percent fractional shortening was calculated as: fractional shorten-ing=[(LVIDdÀLVIDs)/LVIDd]9100%. Heart mass was calculated from the 2-dimensional mode image.
For pulse wave velocity (PWV) measurement ECG leads were placed on 2 front legs and 1 rear leg, and ECG tracing was recorded. Aortic PWV was measured by the transit time method using a 12-MHz Doppler probe (Sonos 5500) at the transverse aortic arch and the abdominal aorta. The distance (d) between 2 points was measured. The time at the transverse aortic arch (t1) and at the abdominal aorta (t2) was defined as the time from the peak of the ECG P wave to the foot of the velocity upstroke. The transit time (Dt) of the flow wave from the upper thoracic aorta to the lower abdominal aorta was determined as the time difference between 2 measurements (t2Àt1). PWV was calculated as d/ Dt (m/s). Each measurement of PWV represents the average of 5 independent determinations per rat.
Na/K-ATPase Measurement
One mL of blood was used for the measurement of erythrocyte Na/K-ATPase activity as previously reported in detail. 32 Total ATPase activity was measured by the production of inorganic phosphate (P i ), and Na/K-ATPase activity was estimated by the difference between ATPase activity in the presence and in the absence of 5 mmol/L ouabain.
Immunoassays
Plasma and urine samples were extracted on Sep-Pak C18 cartridges (Waters) and used for the measurement of marinobufagenin concentration by marinobufagenin competitive fluoroimmunoassay, based on a monoclonal murine antimarinobufagenin 4G4 antibody, performed as recently described in detail. 32 Serum titers of anti-marinobufagenin mAb were determined via solid-phase fluoroimmunoassay as previously reported. 32 Twenty-four-hour excretion of marinobufagenin was calculated as marinobufagenin concentration (pmol/L)924-hour volume of urine (L) and expressed as pmol/ 24-h. LV tissue level of hydroxyproline as a direct measure of total tissue collagen was estimated using the Sircol soluble collagen assay (Biocolor Ltd) and expressed as lg/g tissue.
Western Blotting Analyses
The LV, renal tissue, and ventricular myocytes were homogenized in radioimmunoprecipitation assay buffer (Santa Cruz Biotechnology, Inc) and pretreated in sample buffer (Thermo Fisher Scientific/Invitrogen) for 5 minutes at 90°C for most proteins detection and for 5 minutes at 37°C for collagen detection. Solubilized proteins (30-40 lg protein per lane) were separated by 4% to 12% Tris-Glycine polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (GE Healthcare/Life Sciences). The proteins were visualized using rabbit monoclonal p42/44 mitogen-activated protein kinase (MAPK) (ERK1/2; 1:500; CAT# 4695), rabbit polyclonal TGFb-1 (1:500; CAT# 3709), rabbit monoclonal Mothers Against DPP Homolog (SMAD) 2 (1:1000; CAT# 5339), rabbit polyclonal SMAD4 (1:250; CAT# 9515), rabbit polyclonal MAPK3 (MAPKAPK-3; 1:250; CAT# 3043) antibodies from Cell Signaling Technology; goat polyclonal collagen-1 antibody (1:500; CAT# 1310-01; Southern Biotechnology); rabbit polyclonal protein kinase C (PKC) d (1:1000; CAT# sc-937), phospho-PKCd-Ser643/ 676 (1:1000; CAT# 9376), rabbit polyclonal Friend leukemia integration 1 transcription factor (Fli-1) antibody (1:100; CAT# sc-356) antibodies from Santa Cruz Biotechnology, Inc, followed by incubation with peroxidase-conjugated goat anti-rabbit antibody (1:10 000; CAT# NA934V; GE Healthcare/Life Sciences), or donkey anti-goat antiserum (1:1000; CAT# sc-2020; Santa Cruz, Biotechnology, Inc). Bands were visualized by 1-to 15-minute exposure of nitrocellulose membrane on Premium Blue X-ray film (Phenix Research Products), and optical density was quantified by the laser densitometry (Kodak Molecular Imaging Software, version 5.0). To normalize levels of proteins against levels of glyceraldehydes-3-phosphate dehydrogenase (GAPDH), membranes were stripped and reprobed with a rabbit monoclonal anti-GAPDH (14C10) antibody (1:1000; CAT# 2118; Cell Signaling Technology).
Total RNA Purification and Real-Time qPCR
Real-time qPCR analysis of COL1a2, COL3a1, COL4a1, TGFb1, TGFb2, CTGF1, FN1, MAPK1, SMAD3, and SMAD4 mRNA levels in the left ventricle and kidney was performed by amplification of the resulting cDNAs and normalized to expression of the housekeeping gene (GAPDH) mRNA as an internal standard. In detail, total RNA was purified from the left ventricle (50-60 lg per sample) and renal tissue (50 lg per sample) and using the Qiagen RNeasy Mini Kit (Qiagen Inc). Total RNA samples were then reverse-transcribed to cDNA using the TaqMan Reverse Transcription Kit (Qiagen Inc). Information for the gene primers and the housekeeping gene GAPDH (Qiagen Inc) used for qPCR is presented in Table 1 . qPCR was performed with QuantiFast SYBR Green PCR Kit (Qiagen) in accordance with the manufacturer's protocol with an ABI 7300 Real-Time PCR System (Life Technologies/Applied Biosystems).
Gene expression was analyzed in each sample by the following protocol: activation at 95°C (8 minutes) followed by 40 cycles consisting of a first phase of denaturation at 95°C (10 seconds), and a second phase of annealing/extending at 60°C (30 seconds). Each reaction was performed in triplicate with an inclusion of nontemplate controls in each experiment. A dissociation curve analysis was performed in each experiment to eliminate nonspecific amplification, including primer dimers. The GAPDH C t values were subtracted from the raw sample C t values to obtain the corrected C t . Power conversion (power (2 À(correctedCt) ) was used to convert corrected Ct to relative RNA quantity. Before microarray analysis, the RNA quality and quantity were checked with an Agilent 2100 Bioanalyzer and RNA nano-chips.
Microarray Data Analysis
Total RNA was examined by Agilent Bioanalyzer (Agilent) to establish RNA quantity and quality. Biotinylated, amplified cRNA was generated by reverse transcribing 500 ug RNA into cDNA, and incorporating biotin in the process of converting cDNA into cRNA, using the Illumina TotalPrep RNA amplification kit (Cat # AMIL1791; Illumina). The biotinylated cRNA was hybridized to Illumina RatRef-12 BeadArrays and visualized using a streptavidin-conjugated Cy3-labeled fluorescent reporter. Microarray data were analyzed as previously described 37, 38 with DIANE 6.0.SUITE on JMP11 platform. Average raw microarray signals on each probe were first subjected to filtering by detection P≤0.02 in at least 1 sample as present and converted to its nature log value to obtain normal distribution form on each sample. These normal distributions were further standardized by Z-transform to obtain Z-score normalized gene expression value for statistical analysis. Samples were tested by hierarchical clustering, sample grouped principal component analysis, and sample correlation scatter plots to exclude possible outliners before combining them into different genotyping/treatment groups. Then, independent 1-way ANOVA on sample groups was utilized to identify highly variance probes within each sample group, ANOVA F test P≤0.05 was used as the data global level variance control. Pairwise Z-test was employed with the false discovery rate as the multiple comparison correction. Individual genes were selected by employing the following parameters: |Z-ratio| ≥1.5, Z-test P≤0.05, and false discovery rate ≤0.3. In addition, the average Z-score on all comparison values in this gene should be more than 0 to avoid comparing between extremely small amount gene expression groups. Genes meeting the above criteria were considered significantly changed. The Parametric Analysis of Gene Enrichment (PAGE) algorithm 37 was employed for gene set enrichment analysis by using the Z-ratio of all genes in each sample or each comparison as input against the data set supplied by Gene Ontology Institute 39 and pathway gene set of MIT Broad Institute molecular signature database v5.1. 40 For each gene set (pathway or gene ontology), the enrichment Z-scores for each functional grouping were calculated based on the difference of the average Z-ratio of the individual gene in the gene set to the whole comparison average Z-ratio normalized by the standard derivation of the Z-ratio within this gene set to the entire genes on the microarray. For each specific comparison pair, we performed Z-test of the Z-ratio values for the genes in the gene set to all individual genes' Z-ratio values of the microarray, followed by calculation of a Z-score aggregation on this gene set to describe the scale change. 38 The formula used to calculate the Z-ratio 38 is presented below:
zratioðT À CÞ ¼ zscoreðTÞ À zscoreðCÞ rðzscoreðTÞ À zscoreðCÞÞ where T is treatment group; C is control group; zscore(T) is the zscore of the treatment group T: {zscore T i }, i=1,..,n t (n t is the number of samples in the treatment group T); zscoreðTÞ is the mean of the zscores for treatment group T; zscore(C) is the zscore of the control group C: {zscore C i }, i=1,..,n c (n c is the number of samples in the treatment group C); zscoreðCÞ is the mean of the zscores for control group C; rðzscoreðTÞ À zscoreðCÞÞ is the standard derivation of the difference between the treatment group zscore(T) average to the control group zscore(C) average. 38 In the present study the Z-ratio was calculated for 2 pairwise comparisons: (1) T=HSC Thus, Z-test-generated values, P≤0.05 with false discovery rate ≤0.3, were used as the cutoff criteria for the selection of significant gene set, and each gene set should have at least 3 genes mapped on the microarray. The gene set could be pathway, gene ontology, or any phenotype terms that were collected by a literature mining process. The significant selected gene set (Pathways or GO ontologies) were selected and further grouped according to their interaction categories. If needed, genes for some specific interested gene set were brought into a commercial pathway analysis suite, such as Ingenuity Pathway Analysis Suite or Pathway Studio Suite, to explore details of gene-protein interaction networks and disease associations.
Accession Numbers
The microarray GEO accession numbers for the data reported in this article is GSE62376. This is the super series that includes all 5 experiments, each with their own numbers (links are not released).
Statistical Analysis
Results are reported as meanAEstandard error of the mean. Shapiro-Wilk normality tests (GraphPad Prism software; GraphPad Inc) were conducted for each sample and each variable. All samples passed the normality test (a>0.05). Next, the Bartlett test for equal variances detected that the variances did not differ significantly among the groups. Because our data were consistent with normal distributions with constant variance, the parametric ANOVA was applied for data analysis: 1-way ANOVA, followed by Newman-Keuls test or t test where applicable (GraphPad Prism software). A 2sided P value of <0.05 was considered significant.
Results

Effect of Anti-Marinobufagenin mAb on Clinical, Physiological, and Biochemical Parameters in Hypertensive Dahl-S Rats
The physiological parameters assessed in this study are presented in Table 2 . rats had lower BW and higher systolic BP compared with the animals on an LS intake. Erythrocyte Na/K-ATPase activity was lower and plasma marinobufagenin was 2-fold higher in the HSC versus the LSC group. Urine and water volume, total 24-hour Na + excretion, and FENa increased, urine creatinine and creatinine clearance decreased, and plasma creatinine was unchanged in the HSC versus the LSC group. The volumetric ratio of urine to water was higher in the HSC versus the LCS group by t test ( Figure 1B through 1D). LV, aortic, and kidney weights substantially decreased after anti-marinobufagenin mAb treatment in HSAB compared with nontreated HSC (HSAB, mean LV weight Figure 1D ). Kidney function declined after HS intake (HSC) compared with the LSC group, ie, creatinine clearance was lower and FENa was higher in the HSC group versus the LSC group ( Table 2) . Treatment of hypertensive Dahl-S rats (HSAB) with anti-marinobufagenin mAb significantly increased creatinine clearance ( Table 2) , indicating the normalization of kidney function after the immunoneutralization of marinobufagenin.
Effect of Anti-Marinobufagenin mAb on Cardiovascular Remodeling by Echocardiography
Cardiovascular remodeling in Dahl-S rats on HS diet was accompanied by changes in PWV and in heart structure and function, as determined by echocardiography measurements (Table 3 ). LV internal diameter in systole and diastole decreased, and LV posterior wall thickness, LV, and heart weights increased in HSC versus LSC. This indicated the beginning of the development of a compensated hypertrophy stage in hypertensive Dahl-S rats ( Table 3 ). There was a continued decrease in fractional shortening, an increase in LV internal diameter at end systole and end diastole (LVIDd and LVIDs), and an increase in LV posterior wall thickness at diastole in the same group of Dahl-S rats on HS diet from week 7 to the end of week 8 of HS intake (HSC-7 and HSC-8; Table 3 ). This indicated the initial stage of the development of HF. Treatment of hypertensive Dahl-S rats with antimarinobufagenin mAb in (HSAB-8) attenuated these changes versus the nontreated group (HSC-8) (Table 3) . Thus, immunoneutralization of marinobufagenin reversed the development of HF in hypertensive Dahl-S rats versus nontreated hypertensive animals. Heart and LV weight, estimated by echocardiography, significantly increased in vehicle-treated Dahl-S rats at week 7 of HS versus LSC and continued to increase during week 8 of HS intake. Anti-marinobufagenin mAb treatment reversed this increase in heart and LV mass (HSAB-8 versus HSC-8 [ Table 3 ]). PWV increased in the HSC group compared with the LSC group and was significantly lower after the immunoneutralization of marinobufagenin in the HSAB group versus the HSC group ( Table 3) . Tables 4 and 5 . Zratio is calculated from Z-scores (see Methods for details). Zratio method is used for computing significant fold changes in gene expression between HSC and LSC and between HSAB and HSC. Expression of genes implicated in TGFb profibrotic signaling was significantly upregulated by HS intake versus LS in both the left ventricle and kidneys (column HSC/LSC). Anti-marinobufagenin mAb treatment reversed the expression of these genes in the left ventricle and kidney in HSAB versus HSC (Tables 4 and 5 ; column HSAB/HSC). Sparc, a gene encoding osteonectin, a promoter of calcification and a marker of vascular remodeling, 41, 42 was upregulated by HS intake in HSC versus LSC, and downregulated by anti-marinobufagenin mAb treatment in both the left ventricle (Table 4 ) and kidneys (Table 5 ). In addition, gene MGP (matrix Gla protein), whose active form inhibits calcification, was also upregulated in the kidneys of HSC versus LSC ( Table 5 ). Expression of TIMP1, TIMP2, and TIMP3 mRNAs was significantly higher in the renal tissue in HSC versus LSC and reversed with anti-marinobufagenin mAb treatment (HSAB). Abundance of proteins implicated in the TGFb profibrotic signaling was estimated in the left ventricle by Western blotting (Figure 2 ) and validated by qPCR analysis (Figure 3 ) and in the kidneys by Western blotting (Figure 4 ) and validated by qPCR analysis (Figure 5 ). The abundance of signaling proteins implicated in the TGFb pathway, ie, TGFb-1 and SMAD4, collagen-1, and ERK1/2 and MAPK3, were higher in the left ventricle in hypertensive HSC versus LSC and were downregulated to the control levels in HSAB versus HSC (Figure 2 ). Fli-1 did not change in HSC, nor in HSAB versus control. Cardiac hydroxyproline level, a direct measure of the total amount of tissue collagen, was higher in the hypertrophied left ventricle in HSC compared with LSC (HSC, mean hydroxyproline level, 130AE7 lg/g tissue; LSC, mean hydroxyproline level, 90AE5 lg/g tissue [P<0.01]), and significantly decreased after immunoneutralization of marinobufagenin (HSAB, mean hydroxyproline level, 88AE8 lg/g tissue; HSC, mean hydroxyproline level, 130AE7 lg/g tissue [P<0.01]). The phosphorylated form of PKCd was detected at a higher amount in HSC versus LSC in the presence of unchanged total PKCd abundance, and anti-marinobufagenin mAb reversed phosphorylation of this protein to the control level, making PKCd less active ( Figure 2F ).
Effect of Anti-Marinobufagenin Antibody on mRNA and Protein Expression in Renal Medulla and the Left Ventricle
The data, assessed via Western blotting in the left ventricle, supported the qPCR results, which demonstrated an upregulation of TGFb1, TGFb2, SMAD3, SMAD4, CTGF, Col1a2, Col3a1, Col4a1, and Col5a1 mRNAs in left ventricles from HSC compared with LSC ( Figure 3) . These genes were significantly downregulated after anti-marinobufagenin mAb treatment (HSAB): TGFb1, TGFb2, SMAD3, SMAD4, CTGF, Col1a2, Col3a1, Col4a1, and Col5a1 ( Figure 3A through 3I). The microarray data were supported by Western blotting and qPRC analyses. The abundance of TGFb-1 and collagen-1 proteins, estimated by Western blotting in kidneys, was increased in HSC versus LSC. Anti-marinobufagenin mAb in vivo reversed the amount of these proteins in the renal tissue (Figure 4 ). qPCR analysis of renal tissue showed an increase of TGFb-1, FN1, MAPK1, Col1a2, Col3a1, and Col4a1 mRNA expression in HSC versus LSC ( Figure 5A through 5F) . These genes were downregulated after anti-marinobufagenin mAb treatment in kidneys from HSAB versus HSC ( Figure 5 ).
Heart Failure Network (Microarray Analysis)
The expression of genes related to the Heart Failure Network in the left ventricle, based on PAGE analysis, is presented in Figure 6 . Among the genes upregulated during the development of LV hypertrophy and downregulated by anti-marinobufagenin mAb are the genes related to TGFb signaling, ie, TGFb-1 and TGFb-2, CTGF, MAPK3, SCN3B (sodium channel subunit beta-3), and GRK5 (G protein-coupled receptor kinase 5; related to pathological LV hypertrophy). Some of the genes upregulated in Dahl-S on an HS diet and related to HF, ie, NPPA (natriuretic peptide A) and NPPB (brain natriuretic peptide), were not affected by immunoneutralization of marinobufagenin, indicating a nondownstream location of these markers in the marinobufagenin-Na/K-ATPase profibrotic signaling. The gene expression Heart Failure Network profile shows genes that were upregulated (red) or downregulated (green) in the left ventricle: HSC versus LSC (effect of HS) and HSAB versus HSC (effect of anti-marinobufagenin mAb) ( Figure 6A and 6B ).
Profibrotic Effect of Marinobufagenin in Isolated Ventricular Myocytes
In vitro treatment of cultured ventricular myocytes from control Dahl-S rats with 1 to 10 nmol/L marinobufagenin for 24 hours increased the abundance of proteins from TGFb profibrotic signaling ( Figure 7A through 7D) including TGFb-1, Smad2, Erk1/2, and collagen-1. Phosphorylation of PKCd was dosedependently stimulated by physiological concentrations of marinobufagenin in LV myocytes ( Figure 7E ). In addition, marinobufagenin downregulated a negative regulator of collagen-1 synthesis, Fli-1 ( Figure 7F) , which indicates the activation of Fli-1 profibrotic pathway along with TGFb signaling by marinobufagenin in the cultured LV myocytes.
Discussion
The present study demonstrates the implication of an endogenous steroidal Na/K-ATPase inhibitor, marinobufagenin, in the activation of TGFb-dependent signaling pathway in Dahl-S hypertension via Na/K-ATPase signal transduction. Immunoneutralization of heightened marinobufagenin by antimarinobufagenin mAb reversed upregulated profibrotic TGFb signaling and hypertrophy in cardiovascular and renal tissues from hypertensive Dahl-S rats. Anti-marinobufagenin mAb exhibited pronounced cardiac and renal protective effects in hypertensive Dahl-S rats. In addition, it was demonstrated that marinobufagenin activated TGFb-1 signaling in vitro in cultured cardiac ventricular myocytes from Dahl-S rats.
Upregulated Marinobufagenin Activated TGFb-Dependent Tissue Fibrosis via Na/K-ATPase Cascade
TGFb-dependent profibrotic signaling participates in cardiovascular and renal remodeling in hypertensive Dahl-S rats, 24, 25 because administration of anti-TGFb mAb to hypertensive Dahl-S downregulates expression of genes in TGFb signaling accompanied by antihypertensive and renoprotective effects. 43, 44 The mechanism of stimulation of the TGFb signaling pathway is attributed to several factors, including tissue angiotensin II, 45, 46 which stimulates marinobufagenin in vivo and in vitro in a Dahl-S model, as we previously demonstrated. 7 In the present study the immunoneutralization of marinobufagenin restored erythrocyte Na/K-ATPase activity in hypertensive Dahl-S rats, indicating that the marinobufagenin-Na/K-ATPase complex is another link between angiotensin II and profibrotic signaling, as schematically presented in Figure 8 , and proving that anti-marinobufagenin mAb affects the TGFb signaling upstream. HS intake was accompanied by a concomitant increase in marinobufagenin and erythrocyte Na/ K-ATPase inhibition compared with those in the LSC group.
TGFβ-1 (15 kDa) Collagen-1 This observation is in agreement with our previous findings in the Dahl-S rat model on LS intake. 5, 19, 22 Because the immunoneutralization of marinobufagenin in hypertensive Dahl-S rats resulted in the restoration of Na/K-ATPase activity and downregulation of genes implicated in TGFb-dependent signaling, we conclude that marinobufagenin activates TGFb profibrotic signaling via Na/K-ATPase signal transduction (Figure 8 ). This present observation is supported by previous findings that marinobufagenin and other endogenous Na/K-ATPase ligands mediate signal transduction via Na/K-ATPase. [47] [48] [49] 
TGFb Profibrotic Signaling: Left Ventricle and Kidney Genes and Proteins Expression in a Dahl-S Hypertension Model in the Presence of Anti-Marinobufagenin mAb
In the present study, data on the microarray analysis of the genes implicated in the TGFb pathway were supported by qPCR and Western blotting analyses. The schematic presentation of the signaling pathway induced by marinobufagenin via inhibition of Na/K-ATPase is based on our present findings and those previously reported, 9, [49] [50] [51] [52] [53] [54] and includes canonical (TGFb/ SMAD-dependent), noncanonical (Erk1/2 MAPK), and crosstalk between TGFb and other signaling pathways as schematically presented in Figure 8 . The crosstalk of TGFb and EGFR signaling pathways involves PKCd, which was phosphorylated (ie, activated) in hypertensive Dahl-S and dephosphorylated following immunoneutralization of marinobufagenin in the present study ( Figure 2 ). PKCd was dosedependently phosphorylated by marinobufagenin in the cultured cardiomyocytes ( Figure 7E ). These observations provide an additional indication that marinobufagenin is an important player in profibrotic signaling pathways involved in cardiovascular and renal remodeling in salt-sensitive hypertension. Previously, we and others have reported the upregulation of PKCd in LV sarcolemma from hypertensive Dahl-S rats, 55, 56 which indicate the important contribution of PKC in the pathogenesis of heart diseases. 57, 58 The PKC family is a desirable target for treatment in the scenario of cardiac disorders including heart hypertrophy and HF. The present observation that the treatment of hypertensive rats with antimarinobufagenin mAb was associated with dephosphorylation, ie, deactivation, of PKCd in LV sarcolemma merits future investigation. In addition, the finding that activated inhibitors of metalloproteinases, tissue inhibitor of metalloproteinases, along with activated TGFb signaling (Table 5) , were reversed by anti-marinobufagenin mAb, indicates the complex causative relationship between regulators and mediators of fibrosis. 
Effect of Anti-Marinobufagenin mAb on Cardiac Function, Morphology, and PWV in a Dahl-S Hypertension Model
Higher marinobufagenin levels are associated with increased arterial stiffness, indexed as PWV, and LV mass in clinical studies in patients with normotension 59, 60 and patients with borderline hypertension. 61 In the current study, the treatment with anti-marinobufagenin mAb resulted in the improvement of vascular and cardiac function, ie, a decrease in aortic stiffness decrease estimated by reduced PWV, reduction of heart mass, and restoration of cardiac function estimated by echocardiography (Table 3 ). This restoration was likely caused by the decrease in the activity of TGFb profibrotic signaling and in the decrease of tissue fibrosis by immunoneutralization of marinobufagenin, because systolic BP was moderately affected and remained high after treatment with anti-marinobufagenin mAb in the present study. Our present findings are in agreement with previous observations, that passive and active immunoneutralization of heightened marinobufagenin reversed cardiac and renal remodeling in uremic cardiopathy models. 11, 13 Anti-marinobufagenin antibody exhibited an antihypertensive effect in the animal models of preeclampsia 32, 62 and salt-sensitive hypertension 32 and reduced vascular fibrosis. 63 The vessels from the animals on an HS diet, treated with an antimarinobufagenin mAb in vivo, exhibited improved vasorelaxation by sodium nitroprusside ex vivo versus the untreated aortae. This observation demonstrated a compromised endothelium-independent vasorelaxation caused by a higher aortic wall collagen deposition. 63 In the present study, the decreased aortic stiffness after marinobufagenin immunoneutralization is important in the normalization of vascular compliance by anti-marinobufagenin mAb.
Renoprotective Effect of Anti-Marinobufagenin mAb in Dahl-S Hypertension Model
In the present study, the normalization of renal function by antimarinobufagenin mAb, estimated by creatinine clearance and FENa ( Table 2) , was likely attributable to a decrease of renal fibrosis because it was accompanied by a significant decrease in kidney weight, reduced abundance of collagen I, III, and IV, TGFβ1 (15 kDa) GAPDH (37 kDa) GAPDH (37 kDa) GAPDH (37 kDa) ERK1/2 (42/44 kDa) SMAD2 ( Table 5 ), which is in agreement with our previous observations. 11, 13, 15 In addition, kidney levels of FN1 mRNA, a protein, which provide a scaffold for the deposition of interstitial collagens, 64 dramatically increased in hypertensive Dahl-S rats on HS diet, and the anti-marinobufagenin mAb treatment downregulated FN1 (Table 5 ). Renal hypertrophy observed in hypertensive rats was mostly caused by the activation of profibrotic TGFb signaling, resulting in tissue fibrosis and probably the compensatory hyperplasia of the nondamaged nephrons, as suggested in the literature. 65 The reduction of renal hypertrophy ( Figure 2D ) and restoration of renal function, registered as an increase in creatinine clearance in comparison to the HSC (Table 2) , by immunoneutralization of marinobufagenin, provides a significant input in the normalization of cardiovascular performance even in the presence of elevated BP. Notably, after the immunoneutralization of marinobufagenin in Dahl-S rats on an HS diet, total sodium excretion was reduced, which is expected, because marinobufagenin is a natriuretic hormone. 5, 19, 22 Thus, the immunoneutralization of the profibrotic and natriuretic factor and SMAD-dependent) pathways initiated by marinobufagenin via interaction with Na/K-ATPase. ANGII indicates angiotensin II; c-Src, proto-oncogene tyrosine-protein kinase; EGFR, epidermal growth factor receptor; ERK1/2, mitogen-activated protein kinase (MAPK); Fli-1, Friend leukemia integration 1 transcription factor, a negative regulator of collagen-1 production; NKA, Na/K-ATPase; PLCc, phospholipase C gamma; PKCd, protein kinase C delta; TGFb, transforming growth factor-b; TGFbR, TGFb receptor. The dotted line indicates the release of the procollagen DNA promoter by phosphorylated Fli1; "P" in yellow circle, phosphorylated form of the protein. The chemical structure of marinobufagenin (MBG) is given in the insertion on the left. marinobufagenin manifested a compromised effect on renal function, ie, slightly reduced total 24-hour sodium and urine excretion, and significantly improved renal function by reversing the profibrotic signaling and hypertrophy.
Profibrotic and natriuretic steroidal inhibitor of Na/K-ATPase, marinobufagenin, fits the model of salt-sensitive hypertension, 4 playing a dual role as a natriuretic hormone and a profibrotic factor in the scenario of the compromised sodium renal excretion in Dahl-S rats in comparison to their saltresistant counterparts. 5, 19, 22 This concept suggests that the nonexcreted sodium ions circulate in the body and add to the plasma volume expansion 5, 19, 22 and are also deposited in the skin and muscle interstitial compartments, as was proved in clinical studies and animal models. 66, 67 The biological signature of renal surplus osmolyte excretion is a production of endogenous free water, which helps the renal medullar cells to excrete sodium ions and conserve filtrated water by tubular reabsorption. 66 Sodium homeostasis is substantially controlled by Na/ K-ATPase, which is regulated by steroidal inhibitors including marinobufagenin. It is unclear whether the interstitial sodium ion concentration and interstitial water are higher in HSAB versus HSC in the present study, because the animals had similar BWs under both conditions. The possible role of marinobufagenin in the water/sodium balance in the interstitial compartments deserves detailed exploration in the Dahl-S model, which will add a new dimension to the understanding of sodium handling in salt-sensitive hypertension.
Profibrotic Effect of Marinobufagenin on Cultured LV Myocytes From Dahl-S Rats
The results of the in vitro 24-hour treatment of LV myocytes with marinobufagenin proved that physiological, ie, nanomolar concentrations of marinobufagenin, stimulate TGFb profibrotic signaling in these cells. In addition, marinobufagenin activated a Fli-1-dependent profibrotic pathway in the LV myocytes ( Figure 7 ). Nuclear factor Fli-1 is a negative regulator of collagen-1 biosynthesis. When Fli-1 is phosphorylated by the phosphorylated PKC-d, it releases the procollagen DNA promoter ( Figure 8 ). 54, 68 Interestingly, the crosstalk between Fli-1 and TGFb profibrotic signaling via PKC-d was previously described, 68 as schematically presented in Figure 8 . Previously, we have demonstrated that the Fli-1 pathway is also activated by marinobufagenin in vitro in cultured fibroblasts 15 and rat vascular smooth muscle cells. 26 Our present observation using freshly prepared LV myocytes is in agreement with previous findings 15, 26 and indicates that cardiac myocytes also contribute to the production of the extracellular matrix via both Fli-1 and TGFb profibrotic signaling. Notably, we did not observe the in vivo activation of Fli-1 signaling in the present study in hypertensive Dahl-S rats on HS diet with no changes in the Fli-1 protein in the left ventricle ( Figure 2G ), although the Fli-1 pathway was a predominant profibrotic signal in the animal model of cardiomyopathy. 15, 54 We suggest that in the present study in hypertensive Dahl-S rats with an expedited development of compensated LV hypertrophy, the Fli-1 profibrotic pathway becomes less pronounced in the presence of abundant TGFb signaling under the condition of HS intake.
Conclusions
In salt-sensitive hypertension, heightened endogenous marinobufagenin activates cardiac and renal genes in profibrotic TGFb-dependent signaling implicated in the salt-sensitivity phenomena. Immunoneutralization of marinobufagenin in hypertensive Dahl-S rats downregulates genes associated with TGFb-dependent signaling in the left ventricle and kidneys, reverses heart and renal remodeling, and improves function of the kidneys and cardiovascular system.
